Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shantaram S Joshi

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Leukemia & Lymphoma|September 9, 2017
Regulation of MAPK signaling and implications in chronic lymphocytic leukemiaAshima Shukla, Vipul Shukla, Shantaram S Joshi
Leukemia & Lymphoma|April 11, 2003
Increased apoptosis in B-chronic lymphocytic leukemia cells as a result of cyclin D3 down regulationPeng Wang, Z Steven Pavletic, Shantaram S Joshi
International Journal of Oncology|May 11, 2006
Dendritic cell-based therapy for mantle cell lymphomaCorey M Munger, Julie M Vose, Shantaram S Joshi
Oncotarget|May 28, 2016
Interferon regulatory factor 4 attenuates Notch signaling to suppress the development of chronic lymphocytic leukemiaVipul Shukla, Ashima Shukla, Shantaram S Joshi, et al.
Blood|August 9, 2013
A role for IRF4 in the development of CLLVipul Shukla, Shibin Ma, Richard R Hardy, et al.
International Immunopharmacology|April 30, 2008
A conformationally-biased, response-selective agonist of C5a acts as a molecular adjuvant by modulating antigen processing and presentation activities of human dendritic cellsGanapati V Hegde, Erin Meyers-Clark, Shantaram S Joshi, et al.
BMC Research Notes|December 17, 2014
Experimental validation of predicted subcellular localizations of human proteinsNagendra K Chaturvedi, Riyaz A Mir, Vimla Band, et al.
Cancers|December 23, 2023
PRMT5 as a Potential Therapeutic Target in MYC-Amplified MedulloblastomaDevendra Kumar, Stuti Jain, Don W Coulter, et al.
Vaccine|July 5, 2011
Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine modelGayathri Kollessery, Tara M Nordgren, Amit K Mittal, et al.
In Vivo (Athens, Greece)|December 24, 2002
Enhanced in vitro and in vivo cytotoxicity of umbilical cord blood cells against human breast cancer following activation with IL-15 and colony stimulating factorsTodd R Lovgren, Stefano R Tarantolo, Cody Evans, et al.
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Leukemia & Lymphoma|September 9, 2017
Regulation of MAPK signaling and implications in chronic lymphocytic leukemiaAshima Shukla, Vipul Shukla, Shantaram S Joshi
Leukemia & Lymphoma|April 11, 2003
Increased apoptosis in B-chronic lymphocytic leukemia cells as a result of cyclin D3 down regulationPeng Wang, Z Steven Pavletic, Shantaram S Joshi
International Journal of Oncology|May 11, 2006
Dendritic cell-based therapy for mantle cell lymphomaCorey M Munger, Julie M Vose, Shantaram S Joshi
Oncotarget|May 28, 2016
Interferon regulatory factor 4 attenuates Notch signaling to suppress the development of chronic lymphocytic leukemiaVipul Shukla, Ashima Shukla, Shantaram S Joshi, et al.
Blood|August 9, 2013
A role for IRF4 in the development of CLLVipul Shukla, Shibin Ma, Richard R Hardy, et al.
International Immunopharmacology|April 30, 2008
A conformationally-biased, response-selective agonist of C5a acts as a molecular adjuvant by modulating antigen processing and presentation activities of human dendritic cellsGanapati V Hegde, Erin Meyers-Clark, Shantaram S Joshi, et al.
BMC Research Notes|December 17, 2014
Experimental validation of predicted subcellular localizations of human proteinsNagendra K Chaturvedi, Riyaz A Mir, Vimla Band, et al.
Cancers|December 23, 2023
PRMT5 as a Potential Therapeutic Target in MYC-Amplified MedulloblastomaDevendra Kumar, Stuti Jain, Don W Coulter, et al.
Vaccine|July 5, 2011
Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine modelGayathri Kollessery, Tara M Nordgren, Amit K Mittal, et al.
In Vivo (Athens, Greece)|December 24, 2002
Enhanced in vitro and in vivo cytotoxicity of umbilical cord blood cells against human breast cancer following activation with IL-15 and colony stimulating factorsTodd R Lovgren, Stefano R Tarantolo, Cody Evans, et al.
Pageof 6